PAREXEL INTERNATIONAL APPOINTS MICHAEL E. WOEHLER, Ph.D. AS SENIOR VICE PRESIDENT, CLINICAL RESEARCH SERVICES
BOSTON, MA, August 20, 2001 — PAREXEL International Corporation (Nasdaq: PRXL) today announced the appointment of Michael E. Woehler, Ph.D. as Senior Vice President, Clinical Research Services. Dr. Woehler will be based in Boston and assumes responsibility for the Client Research Units and Client Relations organizations based in North America. Dr.Woehler’s primary focus will be to meet the global needs of PAREXEL’s North America based clients.
"We are extremely pleased to add Michael Woehler to our Clinical Research Services organization," said Carl A. Spalding, President and Chief Operating Officer. "His strong track record in sales and profit growth and his customer-oriented leadership skills will be a strong addition to our senior executive management team.”
Dr. Woehler possesses over twenty-five years of general management, business development, marketing and research experience in the pharmaceutical and biotechnology industries. Prior to joining PAREXEL, he was President and Chief Executive Officer of Mosaic Technologies, a private company marketing unique DNA application technology. Previously, he held several senior-level positions with Pharmacia Biotech for 19 years, most recently serving as President, with responsibility for the worldwide protein/DNA separations business. Dr. Woehler received his B.A. in Biology and Chemistry from Northwestern University and a Ph.D. in Immunology from Marquette University.
PAREXEL is one of the largest contract pharmaceutical outsourcing organizations in the world, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. With a commitment to providing solutions that expedite time-to-market and peak market penetration, PAREXEL has developed significant expertise in clinical trials management, data management, biostatistical analysis, medical marketing, clinical pharmacology, regulatory and medical consulting, industry training and publishing and other drug development consulting services. Its information technology subsidiary, Perceptive Informatics, Inc., provides a variety of technology products and services, including web-based portal solutions and voice and data systems, which are designed to accelerate and enhance the clinical development and launch processes. The Company’s integrated services, therapeutic area depth and sophisticated information technology, along with its experience in global drug development and product launch services, represent key competitive strengths. Headquartered near Boston, MA, PAREXEL operates in 54 locations throughout 35 countries around the world, and as of June 30th had approximately 4,640 employees. Headcount increased to 4,695 with the acquisition of EDYABE, which was announced in July 2001.
This release may contain "forward-looking" statements regarding future results and events, including statements regarding expected financial results, future growth and customer demand that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "expects", "intends", "appears" and similar expressions are intended to identify forward-looking statements. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the cancellation, revision, or delay of contracts, including those contracts in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; government regulation of certain industries and clients; competition and consolidation within the pharmaceutical industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Form 10-Q for the period ended March 31, 2001, as filed with the Securities and Exchange Commission.